Omnicell, Inc. (NASDAQ:OMCL) Short Interest Update

Omnicell, Inc. (NASDAQ:OMCL) was the recipient of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 2,120,000 shares, a growth of 55.9% from the November 15th total of 1,360,000 shares. Based on an average daily trading volume, of 572,300 shares, the short-interest ratio is presently 3.7 days.

Wall Street Analyst Weigh In

OMCL has been the subject of several recent analyst reports. Wells Fargo & Company increased their price target on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. Bank of America reiterated a “neutral” rating and issued a $57.00 price objective (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. JPMorgan Chase & Co. raised their price objective on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Finally, Craig Hallum boosted their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Omnicell presently has an average rating of “Hold” and an average price target of $52.00.

Omnicell Stock Performance

Shares of OMCL traded up $0.05 during mid-day trading on Friday, reaching $46.01. The company had a trading volume of 296,981 shares, compared to its average volume of 535,995. The firm has a 50-day moving average price of $45.32 and a 200 day moving average price of $39.04. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of -117.97, a price-to-earnings-growth ratio of 35.72 and a beta of 0.77. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74.

Insider Buying and Selling at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 2.64% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Several institutional investors have recently modified their holdings of the business. GAMMA Investing LLC grew its stake in shares of Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the period. Nisa Investment Advisors LLC grew its position in Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after buying an additional 1,000 shares during the period. 1620 Investment Advisors Inc. increased its holdings in Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after buying an additional 1,542 shares during the last quarter. CWM LLC raised its position in Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after acquiring an additional 1,236 shares during the period. Finally, Headlands Technologies LLC purchased a new position in shares of Omnicell during the 2nd quarter worth $104,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.